The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Erdafitinib
Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2017-08-03

Last Posted Date: 2024-11-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 35

Registration Number: NCT03238196

Locations: 🇺🇸
Baptist Memorial Hospital MEMPHIS, Memphis, Tennessee, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 3 locations

Inherited CAncer REgistry

Recruiting

Conditions: Cancer

First Posted Date: 2017-07-27

Last Posted Date: 2024-03-06

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 10000

Registration Number: NCT03231891

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Invasive Breast Cancer
Triple Negative Breast Cancer
Stage IV Breast Cancer
HER2 Negative

Interventions: Drug: Atezolizumab
Drug: Carboplatin
Other: Laboratory Biomarker
Other: Quality-of-Life Assessment

First Posted Date: 2017-07-02

Last Posted Date: 2024-12-12

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 106

Registration Number: NCT03206203

Locations: 🇺🇸
Indiana University Health Melvin Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 3 locations

Early Detection of Lung Cancer

Active, not recruiting

Conditions: Lung Cancer

Interventions: Procedure: Biospecimen collection
Procedure: Pulmonary Function Test
Procedure: Computed Tomography (CT)
Other: Laboratory Biomarker

First Posted Date: 2017-06-08

Last Posted Date: 2024-01-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 45

Registration Number: NCT03181256

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

Phase 2

Completed

Conditions: Hematopoietic Cell Transplantation

Interventions: Other: Laboratory Biomarker Analysis
Biological: Quadrivalent Inactivated Influenza Vaccine
Biological: Trivalent Influenza Vaccine

First Posted Date: 2017-06-07

Last Posted Date: 2024-12-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 124

Registration Number: NCT03179761

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States

and more 1 locations

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non-Small Cell Lung Carcinoma

Interventions: Drug: Afatinib
Biological: Necitumumab
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-02-15

Last Posted Date: 2022-04-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 22

Registration Number: NCT03054038

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Phase 2

Withdrawn

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IV Non-Small Cell Lung Cancer

Interventions: Biological: Nivolumab
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-01-18

Last Posted Date: 2018-04-25

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT03023904

Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma

Phase 2

Terminated

Conditions: Adenocarcinoma

Interventions: Drug: Avelumab

First Posted Date: 2016-12-21

Last Posted Date: 2022-04-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 8

Registration Number: NCT03000179

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer

Not Applicable

Terminated

Conditions: Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma

Interventions: Procedure: Bronchoscopy with Bronchoalveolar Lavage
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-10-18

Last Posted Date: 2019-09-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 9

Registration Number: NCT02937402

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Hatha Yoga in Breast Cancer Survivors

Not Applicable

Terminated

Conditions: Breast Carcinoma
Lymphedema

Interventions: Procedure: Yoga
Other: tape measurement of arm
Other: Quality-of-Life Assessment
Other: ldex measurement of arms

First Posted Date: 2016-10-04

Last Posted Date: 2019-03-26

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 27

Registration Number: NCT02923037

Locations: 🇺🇸
Vanderbilt University School of Nursing, Nashville, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy